PDCD1 and non-small cell lung carcinoma: However, despite the promising efficacy of immunotherapy in NSCLC, the success of ICIs is currently limited to a small subset of patients, with the overall response rate to anti–PD-1 or PD-L1 therapy only 20%- 30% (2, 3).